Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 75 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/2/2008 First Published: 1/25/2007


1.		Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				SPRI-P04445 EU-20654, NCT00266799, SPRI-PELICAN


2.		A Randomized Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Diagnostic, Treatment				Active				18 to 65				Other				LITE Randomized Pilot Study NCT00531973


3.		Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059 AM2)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				65 and over				Pharmaceutical / Industry				P05059 NCT00604968


4.		A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				DOXIL-BCA-3001 NCT00091442


5.		Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2303 NCT00262990

Last Modified: 1/14/2009 First Published: 2/5/2007


6.		Phase III Randomized Study of Adjuvant Therapy Comprising Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Bevacizumab in Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E5103 E5103, NCT00433511


7.		Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence and to Prolong the Platinum Free Interval

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				Other				MITO-8 EudraCT number: 2008-001755-22, NCT00657878

Last Modified: 12/10/2008 First Published: 9/9/2005


8.		Phase I/II Study of Ixabepilone and Pegylated Doxorubicin HCl Lipsome in Women With Previously Treated Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer (Phase I Closed to Accrual as of 12/6/07)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				AECM-0504007857 NCI-7229, 7229, NCT00182767


9.		Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				GEICAM 2003-03 NCT00129896

Last Modified: 7/18/2007 First Published: 5/23/2006


10.		Phase I/II Study of Doxorubicin HCl Liposome, Melphalan, and Bortezomib in Patients With Relapsed or Refractory Stage I-III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CPMC-AAAB6443 NCT00334932

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute